Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Europe's revised BSE proposal would allow two-year exemption of marketed "medicinal" products.

This article was originally published in The Gray Sheet

Executive Summary

EUROPEAN UNION BSE RISK MATERIAL PROPOSAL WOULD ALLOW TWO-YEAR EXEMPTION for "medicinal products" already on the market to eliminate use of "specified risk materials" (SPM) for transmissible spongiform encephalopathies (including bovine SEs, often called "mad cow" disease).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel